KR900004330A - 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 - Google Patents
약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 Download PDFInfo
- Publication number
- KR900004330A KR900004330A KR1019890011531A KR890011531A KR900004330A KR 900004330 A KR900004330 A KR 900004330A KR 1019890011531 A KR1019890011531 A KR 1019890011531A KR 890011531 A KR890011531 A KR 890011531A KR 900004330 A KR900004330 A KR 900004330A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- glycerin
- enhancer composition
- enhancer
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (21)
- (a) 경피식으로 흡수가능한 약물, (b) C₂또는 C₃알코올, C₃또는 C₄디올, DMSO, DMF, 음, 1-n-도데실-시클라자시클로헵탄-2-온, N-메틸-피롤리돈 및 N-(2-히드록시에틸)피롤리돈 및 이들의 혼합물로 구성된 그룹에서 선택한 용매 그리고 세포의 포 장해 화합물로 구성된 증대제 조성물 그리고 (c) 자극을 감소시키는데 효과있는 양의 글리세린으로 필수적으로 구성된 약물/증대제 조성물의 유효량을 피부의 예정된 면에 도포하는 것을 포함하는 피부자극 성질을 가지는 약물/증대제 조성물에 의해 야기된 피부자극 감소방법.
- 제1항에 있어서, 세포외막 장해화합물이 라우린산메틸, 올레인산, 올레일 알코올, 일올레인산 글리세롤, 이올레인산, 글리세롤 및 삼올레인산 글리세롤 및 이들의 혼합물로 구성된 그룹에서 선택된 구성부분(member)인 방법.
- 제1항 및 제2항에 있어서, 글리세린 함유 약물/증대제 조성물을 이환위치에 주여하는 방법.
- 제1항 및 제2항에 있어서, 글리세린 함유 약물/증대제 조성물을 증검시키고 피부와 접촉시켜 유지시키는 저장기 속에 넣어서 저장기 바닥을 형성하는 투과성막을 통해 도포위치에서 피부표면에 투여하는 방법.
- 제1항 및 제4항에 있어서, 글리세린 함유 약물/증대제 조성물이 약 0.1 내지 70중량% 글리세린을 포함하는 방법.
- 제1항 내지 제4항에 있어서, 글리세린 함유 약물/증대제 조성물이 약 1.0 내지 50중량%의 글리세린을 포함하는 방법.
- 제1항 내지 제4항에 있어서, 약물/증대제 조성물이 약 5.0 내지 20.0중량%의 글리세린을 포함하는 방법.
- (a) 경피식 흡수가능한 약물, (b) C₂또는 C₃알코올, C₃또는 C₄디올, DMSO, DMF, 음, 1-n-도데실-시클라자시클로헵탄-2-온, N-메틸-피롤리돈 및 N-(2-히드록시에틸)피롤리돈 및 이들의 혼합물로 구성된 그룹에서 선택한 용매 그리고 세포외막 장해 화합물의 효능있는 증대제 량으로서 필수적으로 구성된 증대제 조성물 그리고 (c) 자극을 감소시키는데 효과있는 양의 글리세린으로 필수적으로 구성된 감소된 피부자극 성질을 가지는 약물을 경피식으로 투여하는 약물/증대제 조성물
- 제8항에 있어서, 세포-외막 장해 화합물이 라우린산 메틸, 올레인산, 올레인산 알코올, 일올레인산 글리세롤, 이올레인산 글리세롤 및 심올레인산 글리세롤 및 이들의 혼합물로 구성된 그룹에서 선택된 구성부분인 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 에탄올로 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 DMSO를 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 프로필렌 글리콜을 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 1-도데실-아자시클로헵탄-2-온을 포함하는 조성물.
- 제8항 및 제9항에 있어서, 증대제 조성물이 용매로서 프로필렌 글리콜을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 라우린산메틸을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 이올레인산 글리세롤을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 일올레인산 글리세롤을 포함하는 조성물.
- 제10 내지 제14항에 있어서, 증대제 조성물이 세포-외막 장해 화합물로서 올레인산을 포함하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 0.1 내지 70.0중량% 범위의 양으로 존재하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 1.0 내지 50.0중량%의 범위의 양으로 존재하는 조성물.
- 제8항 내지 제18항에 있어서, 글리세린이 약 5.0 내지 약 20.0중량% 범위의 양으로 존재한 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/240,688 US4855294A (en) | 1988-09-06 | 1988-09-06 | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
US240,688 | 1988-09-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900004330A true KR900004330A (ko) | 1990-04-12 |
KR0143916B1 KR0143916B1 (ko) | 1998-07-15 |
Family
ID=22907535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890011531A KR0143916B1 (ko) | 1988-09-06 | 1989-08-12 | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US4855294A (ko) |
EP (1) | EP0416137B1 (ko) |
JP (1) | JP2953625B2 (ko) |
KR (1) | KR0143916B1 (ko) |
AT (1) | ATE96678T1 (ko) |
CA (1) | CA1332570C (ko) |
DE (1) | DE68910520T2 (ko) |
ES (1) | ES2053882T3 (ko) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0437225B1 (de) * | 1990-01-10 | 1994-04-20 | F. Hoffmann-La Roche Ag | Topische Präparate |
US5160741A (en) * | 1990-07-06 | 1992-11-03 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5130139A (en) * | 1990-07-06 | 1992-07-14 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
US5705185A (en) * | 1991-09-25 | 1998-01-06 | Beta Pharmaceuticals Co. | Transdermal delivery of estradiol and process for manufacturing said device |
US5276079A (en) * | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
US6284754B1 (en) * | 1992-01-20 | 2001-09-04 | Schwarz Pharma Ag | Pharmaceutical compositions containing 1-oleylazacycloheptan-2-one as enhancing agent of transport across biological membranes |
ATE184473T1 (de) * | 1992-06-11 | 1999-10-15 | Theratech Inc | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung |
CA2140901A1 (en) * | 1992-07-23 | 1994-02-05 | Naruhito Higo | Basal drug composition for percutaneous administration and pharmaceutical composition thereof |
DE4429667C2 (de) * | 1994-08-20 | 1996-07-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
DE19610396C2 (de) * | 1996-03-16 | 1998-11-26 | Krewel Meuselbach Gmbh | Dimethylsulfoxid-haltige topische Zubereitung |
EP0942697A1 (en) * | 1996-10-30 | 1999-09-22 | THERATECH, INC. (a Delaware Corporation) | Fatty acid esters of lactic acid salts as permeation enhancers |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
ZA984649B (en) * | 1997-06-13 | 1999-12-17 | Cryopreservation Tech Cc | "Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes". |
IL136042A (en) | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
US6180133B1 (en) * | 1997-11-25 | 2001-01-30 | Watson Pharmaceuticals, Inc. | Antioxidant composition for topical/transdermal prevention and treatment of wrinkles |
US6136799A (en) * | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
JP2002519366A (ja) | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US6238683B1 (en) | 1998-12-04 | 2001-05-29 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
WO2000072883A2 (en) * | 1999-06-02 | 2000-12-07 | Aviana Biopharm | Pharmaceutical transdermal compositions |
US6232366B1 (en) | 1999-06-09 | 2001-05-15 | 3M Innovative Properties Company | Pressure sensitive conductive adhesive having hot-melt properties and biomedical electrodes using same |
KR100369779B1 (ko) * | 1999-07-12 | 2003-01-29 | 주식회사 엘지생명과학 | 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형 |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
ES2272416T3 (es) * | 2000-05-01 | 2007-05-01 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Preparaciones anhidras topicas para la piel. |
US20060121103A1 (en) * | 2000-05-11 | 2006-06-08 | Kenneth Kirby | Transdermal delivery system |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10040592A1 (de) * | 2000-08-15 | 2002-03-07 | Aventis Res & Tech Gmbh & Co | Formulierung zur verbesserten Aufnahme von Wirkstoffen und deren Verwendung |
JP4358978B2 (ja) * | 2000-09-05 | 2009-11-04 | 日東電工株式会社 | 経皮吸収製剤 |
KR20030028253A (ko) * | 2001-09-27 | 2003-04-08 | (주)지씨아이 | 잔탄검과 알긴을 이용한 항고지단백혈증 경피투과제제의제조 |
US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
ES2532906T5 (es) | 2002-10-25 | 2022-03-23 | Foamix Pharmaceuticals Ltd | Espuma cosmética y farmacéutica |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20040247654A1 (en) * | 2003-06-05 | 2004-12-09 | 3M Innovative Properties Company | Hydrophilic adhesives for delivery of herbal medicines |
US9278155B2 (en) | 2003-06-05 | 2016-03-08 | 3M Innovative Properties Company | Adhesive compositions, articles incorporating same and methods of manufacture |
JP4596751B2 (ja) * | 2003-06-11 | 2010-12-15 | 帝國製薬株式会社 | 消炎鎮痛貼付剤 |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
DE102004009903A1 (de) * | 2004-02-26 | 2005-09-22 | Grünenthal GmbH | Pflaster mit reduzierter Hautirritation |
KR20070093079A (ko) * | 2004-11-29 | 2007-09-17 | 암브리아 더마톨로지 아베 | 적어도 세 개의 다른 디올을 포함하는 조성물 |
WO2006060515A2 (en) * | 2004-12-02 | 2006-06-08 | Omp, Inc. | System for improved percutaneous absorption of skin benefiting agents |
US7999023B2 (en) | 2004-12-03 | 2011-08-16 | 3M Innovative Properties Company | Process for making pressure sensitive adhesive hydrogels |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
US8147815B2 (en) * | 2005-12-16 | 2012-04-03 | Celmatrix Corporation | Topical administration carrier composition and therapeutic formulations comprising same |
US20070179121A1 (en) * | 2006-02-02 | 2007-08-02 | Plott R T | Method of treating pediatric patients with corticosteroids |
US7645252B2 (en) * | 2006-05-16 | 2010-01-12 | Barbara Brooke Jennings-Spring | Body or plant part dressing |
US7905852B2 (en) * | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
EP2626063B1 (en) | 2006-10-17 | 2022-03-16 | Nuvo Pharmaceuticals Inc. | Diclofenac gel |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
EP2117524B8 (en) * | 2007-01-29 | 2019-09-25 | National Research Council of Canada | Use of catecholamines and related compounds as anti-angiogenic agents |
JP5313868B2 (ja) * | 2007-03-02 | 2013-10-09 | テイカ製薬株式会社 | 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤 |
US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
EP2230911A4 (en) * | 2007-12-21 | 2013-07-03 | Zars Pharma Inc | STAMPS, FORMULATIONS, AND RELATED METHODS FOR THE TRANSDERMAL DELIVERY OF ALPRAZOLAM AND OTHER MEDICAMENTS |
EP2242476A2 (en) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
AU2014209376B2 (en) | 2013-01-24 | 2017-03-16 | Irhythm Technologies, Inc. | Physiological monitoring device |
WO2015048109A1 (en) | 2013-09-30 | 2015-04-02 | 3M Innovative Properties Company | Silicone-polyether copolymers, adhesives and medical articles comprising same, and methods of making same |
KR102335784B1 (ko) | 2014-10-31 | 2021-12-06 | 아이리듬 테크놀로지스, 아이엔씨 | 무선 생리학적 모니터링 기기 및 시스템 |
WO2017044458A1 (en) * | 2015-09-08 | 2017-03-16 | The University Of Toledo | Treatment of raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (trpm-8) |
CN105833279B (zh) | 2016-05-30 | 2021-06-22 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US9962444B2 (en) | 2016-09-27 | 2018-05-08 | Shane Malek | Pharmacokinetically extended action topical hair growth formulation, and administration method |
US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
WO2020201878A1 (en) | 2019-04-01 | 2020-10-08 | 3M Innovative Properties Company | Process for making pressure sensitive adhesive hydrogels |
EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
AU2021218704B2 (en) | 2020-02-12 | 2023-11-02 | Irhythm Technologies, Inc. | Non-invasive cardiac monitor and methods of using recorded cardiac data to infer a physiological characteristic of a patient |
CA3188325A1 (en) | 2020-08-06 | 2022-02-10 | Jeff ABERCROMBIE | Adhesive physiological monitoring device |
CN116322498A (zh) | 2020-08-06 | 2023-06-23 | 意锐瑟科技公司 | 生理监测装置的电子组件 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1408384A (en) * | 1920-06-21 | 1922-02-28 | Thomas J Newlyn | Cosmetic lotion |
CA1165240A (en) * | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
EP0095813A3 (en) * | 1982-06-01 | 1985-05-08 | THE PROCTER & GAMBLE COMPANY | Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine |
GR77517B (ko) * | 1982-06-30 | 1984-09-24 | Procter & Gamble | |
DE3382566D1 (de) * | 1982-09-30 | 1992-07-02 | Lancaster Group Ag | Glycerinhaltige kosmetische mittel. |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
EP0267617B1 (en) * | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
-
1988
- 1988-09-06 US US07/240,688 patent/US4855294A/en not_active Expired - Lifetime
-
1989
- 1989-08-08 DE DE89114676T patent/DE68910520T2/de not_active Expired - Fee Related
- 1989-08-08 EP EP89114676A patent/EP0416137B1/en not_active Expired - Lifetime
- 1989-08-08 AT AT89114676T patent/ATE96678T1/de not_active IP Right Cessation
- 1989-08-08 ES ES89114676T patent/ES2053882T3/es not_active Expired - Lifetime
- 1989-08-12 KR KR1019890011531A patent/KR0143916B1/ko not_active IP Right Cessation
- 1989-09-05 JP JP1228476A patent/JP2953625B2/ja not_active Expired - Lifetime
- 1989-09-05 CA CA000610288A patent/CA1332570C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE68910520T2 (de) | 1994-04-07 |
JP2953625B2 (ja) | 1999-09-27 |
CA1332570C (en) | 1994-10-18 |
EP0416137B1 (en) | 1993-11-03 |
ES2053882T3 (es) | 1994-08-01 |
DE68910520D1 (de) | 1993-12-09 |
EP0416137A1 (en) | 1991-03-13 |
KR0143916B1 (ko) | 1998-07-15 |
JPH02115131A (ja) | 1990-04-27 |
US4855294A (en) | 1989-08-08 |
ATE96678T1 (de) | 1993-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900004330A (ko) | 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법 | |
AU568590B2 (en) | Penetration enhancers for transdermal drug delivery of systemic agents | |
US4942158A (en) | Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol | |
DE69229506T2 (de) | Ketorolac enthaltender warmer umschlag | |
ES2042527T3 (es) | Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica. | |
EP0178140A2 (en) | Transdermal therapeutic systems for the administration of nalozone, naltrexone and nalbuphine | |
KR840009035A (ko) | 피부 침투 치료 시스템용 매트릭스 조성물 | |
LU91973I2 (fr) | Fentanyl | |
DZ1067A1 (fr) | Nouvelles préparations pharmaceutiques à emission prolongée. | |
BR9909796B1 (pt) | "derivados de piperidinopirimidina para aplicação tópica" | |
ATE184473T1 (de) | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung | |
US5438067A (en) | Medetomidine preparations for transdermal administration | |
KR960704579A (ko) | 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin) | |
KR930007445A (ko) | 국소 적용 배합물의 침투 증가방법 | |
KR850004389A (ko) | 경피침투가 증진된 생리학적 활성제제의 제조방법 | |
CA2360300C (en) | A transdermal composition of an antivomiting agent and a preparation containing the same | |
EP0651993B1 (en) | Percutaneously administrable base composition and drug composition prepared therefrom | |
US4777047A (en) | Transdermal application form of calcium antagonists | |
US5464628A (en) | Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally | |
US5422118A (en) | Transdermal administration of amines with minimal irritation and high transdermal flux rate | |
JPH03505835A (ja) | 経皮ドラッグデリバリーシステム | |
KR880005946A (ko) | 전신 약품의 경피 투여용 침투 증강제 | |
KR920700704A (ko) | pH-조절된 조건하 약리학적 화합물 투여용 개선된 경피체계 | |
KR100390870B1 (ko) | 경피투여용 항구토제 조성물 및 이를 포함하는 제제 | |
Krishnakumaran | Dependence of juvenile hormone activity on haemolymph factor in Tenebrio molitor pupae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120328 Year of fee payment: 15 |
|
EXPY | Expiration of term |